Financial Analysis Professional
About the job
- A bachelor's degree in Finance, Accounting, Economics, Business Administration, or a related field is required.
- Four to seven years of experience in FP&A, Commercial Finance, Financial Analysis, or Business Finance is required.
- Professional certifications such as CMA, ACCA, CFA, or an MBA are advantageous.
- Proven experience in forecasting, budgeting, and management reporting is required.
- Strong experience in commercial analysis and profitability management is required.
- Demonstrated success in business partnering with commercial and cross-functional teams is required.
- Evidence of contribution to business growth and process improvement initiatives is required.
- Conduct daily in-market sales and stock performance analysis to provide timely and accurate business insights.
- Monitor and evaluate pricing, discounts, and profitability by SKU and account to support margin improvement.
- Support forecasting, budgeting, and financial planning processes by validating assumptions and improving the accuracy of outcomes.
- Partner with commercial and operational teams to support key business decisions through cash flow tracking and financial analysis, including KSA-related projects.
- Manage and control online revenue streams and stock performance across digital platforms.
- Prepare regular financial and management reports to highlight risks, opportunities, and performance trends.
- Provide actionable recommendations to improve business performance, operational efficiency, and profitability.
- Collaborate with internal stakeholders to strengthen financial discipline and support strategic initiatives.
- Professional certifications such as CMA, ACCA, CFA, or an MBA.
About the company
EVA Pharma develops and manufactures affordable medicines for global markets, focusing on 12 therapeutic areas such as anti-infectives, metabolic health, oncology, and pediatrics. It operates four manufacturing facilities with a 5,000-strong team and produces over one million healthcare products daily. The company runs two regional research centers that use AI-driven prediction and mRNA R&D to develop biological products and first-of-its-kind capabilities in the Middle East and Africa. EVA Pharma distributes its products to more than 60 countries and seeks to expand access to high-quality medicines worldwide. Its differentiation comes from its scale, regional R&D capabilities, and commitment to sustainable access, aiming to meet pressing, unmet disease needs with reliable supply.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Al Sharikat, Egypt
Founded
1997
Get referred to Eva Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Egypt’s December 2024 insulin approval opens exportable manufacturing revenues and credibility with regulators.
- November 2025 EVA Pharma Oncology targets 22 million packs annually, with 11 more treatments planned.
- Access-heavy partnerships with Gilead, BeiGene, and Porton create multiple near-term revenue streams.
What critics are saying
- Gilead’s generic lenacapavir supply starts 2027, so execution delays destroy EVA Pharma’s moat.
- Oncology launches need Egypt market uptake; BRUKINSA, TEVIMBRA, and seven in-house products face entrenched competitors.
- Any FDA, EDA, or Gilead tech-transfer setback blocks EVA Pharma’s pivot into high-value biologics.
What makes Eva Pharma unique
- Egypt’s 2024 Lilly insulin approval proves EVA Pharma can localize complex biologics manufacturing.
- The 2024 Gilead lenacapavir license makes EVA Pharma Africa’s sole local generic producer.
- The 2025 BeiGene deal and 2025 Porton MOU extend EVA Pharma beyond generics into oncology and CAR-T.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Hybrid Work Options